Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis

被引:68
|
作者
Saito, Kosuke [1 ]
Uebanso, Takashi [2 ]
Maekawa, Keiko [1 ]
Ishikawa, Masaki [1 ]
Taguchi, Ryo [1 ]
Nammo, Takao [2 ]
Nishimaki-Mogami, Tomoko [3 ]
Udagawa, Haruhide [2 ]
Fujii, Masato [4 ]
Shibazaki, Yuichiro [4 ]
Yoneyama, Hiroyuki [4 ]
Yasuda, Kazuki [2 ]
Saito, Yoshiro [1 ]
机构
[1] Natl Inst Hlth Sci, Div Med Safety Sci, Setagaya Ku, 1-18-1 Kamiyoga, Tokyo 1588501, Japan
[2] Natl Ctr Global Hlth & Med, Diabet Res Ctr, Res Inst, Dept Metab Disorder,Shinjuku Ku, Tokyo 1628655, Japan
[3] Natl Inst Hlth Sci, Div Biochem, Setagaya Ku, Tokyo 1588501, Japan
[4] Stel Inst & Co Inc, Tokyo 1060044, Japan
来源
SCIENTIFIC REPORTS | 2015年 / 5卷
关键词
FATTY LIVER-DISEASE; ACCUMULATION; INFLAMMATION; ASSOCIATION; POPULATION; PREVALENCE; EXPRESSION; CIRRHOSIS; PLASMA; INJURY;
D O I
10.1038/srep12466
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Nonalcoholic steatohepatitis (NASH) is a major health problem since it often leads to hepatocellular carcinoma. However, the underlying mechanisms of NASH development and subsequent fibrosis have yet to be clarified. We compared comprehensive lipidomic profiles between mice with high fat diet (HFD)-induced steatosis and STAM mice with NASH and subsequent fibrosis. The STAM mouse is a model that demonstrates NASH progression resembling the disease in humans: STAM mice manifest NASH at 8 weeks, which progresses to fibrosis at 12 weeks, and finally develop hepatocellular carcinoma. Overall, 250 lipid molecules were detected in the liver using liquid chromatography-mass spectrometry. We found that STAM mice with NASH presented a significantly higher abundance of sphingolipids and lower levels of triacylglycerols than the HFD-fed control mice. The abundance of certain fatty acids in phospholipid side chains was also significantly different between STAM and control mice, although global levels of phosphatidylcholines and phosphatidylethanolamines were comparable. Finally, increase in levels of acylcarnitines and some diacylglycerols was observed in STAM mice toward the fibrosis stage, but not in age-matched control mice. Our study provides insights into the lipid status of the steatotic, NASH, and fibrotic liver that would help elucidate the molecular pathophysiology of NASH progression.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] THE THERAPEUTIC EFFECT OF EICOSAPENTAENOIC ACID AGAINST HEPATIC FIBROSIS IN A RAT MODEL OF NONALCOHOLIC STEATOHEPATITIS
    Kajikawa, Satoshi
    Imada, Kazunori
    Takeuchi, Takashi
    Shimizu, Yutaka
    Kawashima, Akiko
    Harada, Tsuyoshi
    Kawano, Hiroyuki
    Notsu, Tatsuto
    Mizuguchi, Kiyoshi
    HEPATOLOGY, 2010, 52 (04) : 1055A - 1055A
  • [32] Hepatic Myeloid Cell Diversity During Fibrosis and Nonalcoholic Steatohepatitis
    Troutman, Ty Dale
    Seidman, Jason S.
    Link, Verena M.
    Hosseini, Mojgan
    Sakai, Mashito
    Bruni, Cassi
    Ouyang, Zhengyu
    Pasillas, Martina
    Glass, Christopher K.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [33] Family History of Diabetes and Risk of Nonalcoholic Steatohepatitis and Hepatic Fibrosis
    Loomba, Rohit
    Abraham, Maria
    Unalp-Arida, Aynur
    Wilson, Laura
    Lavine, Joel E.
    Doo, Edward
    Bass, Nathan M.
    GASTROENTEROLOGY, 2011, 140 (05) : S987 - S988
  • [34] Nonalcoholic steatohepatitis with improved hepatic fibrosis after weight reduction
    Fujikawa, K
    Ohata, K
    Honda, T
    Miyazoe, S
    Ichikawa, T
    Ishikawa, H
    Hamasaki, K
    Nakao, K
    Toriyama, K
    Eguchi, K
    INTERNAL MEDICINE, 2004, 43 (04) : 289 - 294
  • [35] Serologic Biomarkers for Hepatic Fibrosis in Obese Children with Nonalcoholic Steatohepatitis
    Joo, Jung Yeon
    Yoo, In Hyuk
    Yang, Hye Ran
    PEDIATRIC GASTROENTEROLOGY HEPATOLOGY & NUTRITION, 2024, 27 (04) : 236 - 245
  • [36] Collagen Characterization in a Model of Nonalcoholic Steatohepatitis with Fibrosis; A Call for Development of Targeted Therapeutics
    Pellicano, Anthony J.
    Spahn, Kiera
    Zhou, Ping
    Goldberg, Itzhak D.
    Narayan, Prakash
    MOLECULES, 2021, 26 (11):
  • [37] Effects of BMS-986036 (pegylated fibroblast growth factor 21) on hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis
    Krupinski, John
    Morgan, Nathan
    Kozhich, Alex
    Chiney, Manoj
    Morin, Paul
    Christian, Rose
    HEPATOLOGY, 2016, 64 : 749A - 749A
  • [38] Hepatocyte nuclear receptor SHP suppresses inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis
    Zou, An
    Magee, Nancy
    Deng, Fengyan
    Lehn, Sarah
    Zhong, Cuncong
    Zhang, Yuxia
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (22) : 8656 - 8671
  • [39] Effect of Pioglitazone on Insulin Sensitivity and Hepatic Mitochondrial Function in a Mouse Model of Nonalcoholic Steatohepatitis
    Kalavalapalli, Srilaxmi
    Abdo, Kaitlyn
    Jose, Dhanya
    Andrews, Paige
    Cusi, Kenneth
    Sunny, Nishanth E.
    DIABETES, 2017, 66 : A676 - A676
  • [40] PITAVASTATIN PREVENT FIBROSIS IN NONALCOHOLIC STEATOHEPATITIS MODEL RAT
    Miyaki, Tomokatsu
    Nojiri, Shunsuke
    Sugauchi, Fuminako
    Sakamoto, Tomoyuki
    Senda, Katsuhiro
    Joh, Takashi
    HEPATOLOGY, 2008, 48 (04) : 847A - 848A